// App-Quantinova.ai

237P : CHARACTERISTICS OF DE NOVO RESISTANCE TO ANDROGEN TARGETING THERAPEUTICS (AR TX) THROUGH CIRCULATING TUMOR CELLS (CTCS) ANALYSIS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS

Researchers

Presenter

  • R.M. Bambury

Principal Investigators

  • J. Louw

  • R. Krupa

  • D. Danila

  • Z. Arslan

  • N.A. Schreiber

  • A. Jendrisak

  • D. Marrinucci

  • R. Dittamore

  • H.I. Scher

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Translational Resear

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Prostate specific antigen

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved